• Vector Science and Therapeutics filed a US provisional patent for an orthopedic tissue-regeneration platform combining peptides with autologous PRP or PRF.
• Platform targets improved healing by pairing regenerative peptides with platelet-rich biologics to drive a stronger response than either alone.
• Patent also covers adjunct formulations intended to reduce interference from common surgical pain-control or infection-prevention agents on repair cells.
• Peptides were reclassified out of FDA’s higher-risk compounding category earlier this year; an advisory committee recommended several for the compounding list.
• Program remains in development with no clinical studies; candidates described are investigational and not approved for any indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via CNW (Ref. ID: 202608200730CANADANWCANADAPR_C9438) on August 20, 2026, and is solely responsible for the information contained therein.